BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 27834739)

  • 1. Systematic approaches to identify E3 ligase substrates.
    Iconomou M; Saunders DN
    Biochem J; 2016 Nov; 473(22):4083-4101. PubMed ID: 27834739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A label-free quantitative proteomics strategy to identify E3 ubiquitin ligase substrates targeted to proteasome degradation.
    Burande CF; Heuzé ML; Lamsoul I; Monsarrat B; Uttenweiler-Joseph S; Lutz PG
    Mol Cell Proteomics; 2009 Jul; 8(7):1719-27. PubMed ID: 19376791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design Principles Involving Protein Disorder Facilitate Specific Substrate Selection and Degradation by the Ubiquitin-Proteasome System.
    Guharoy M; Bhowmick P; Tompa P
    J Biol Chem; 2016 Mar; 291(13):6723-31. PubMed ID: 26851277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timer-based proteomic profiling of the ubiquitin-proteasome system reveals a substrate receptor of the GID ubiquitin ligase.
    Kong KE; Fischer B; Meurer M; Kats I; Li Z; Rühle F; Barry JD; Kirrmaier D; Chevyreva V; San Luis BJ; Costanzo M; Huber W; Andrews BJ; Boone C; Knop M; Khmelinskii A
    Mol Cell; 2021 Jun; 81(11):2460-2476.e11. PubMed ID: 33974913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the Rampant Expansion of Ubiquitin Proteomics.
    Rose A; Mayor T
    Methods Mol Biol; 2018; 1844():345-362. PubMed ID: 30242720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative Lys-ϵ-Gly-Gly (diGly) proteomics coupled with inducible RNAi reveals ubiquitin-mediated proteolysis of DNA damage-inducible transcript 4 (DDIT4) by the E3 ligase HUWE1.
    Thompson JW; Nagel J; Hoving S; Gerrits B; Bauer A; Thomas JR; Kirschner MW; Schirle M; Luchansky SJ
    J Biol Chem; 2014 Oct; 289(42):28942-55. PubMed ID: 25147182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ubiquitin proteasome system in immune regulation and therapeutics.
    Bhat SA; Vasi Z; Adhikari R; Gudur A; Ali A; Jiang L; Ferguson R; Liang D; Kuchay S
    Curr Opin Pharmacol; 2022 Dec; 67():102310. PubMed ID: 36288660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gold for ubiquitin in Vancouver: First Conference on Proteomics of Protein Degradation and Ubiquitin Pathways held June 6-8, 2010 in Vancouver, University of British Columbia, organized By Lan Huang, Thibault Mayor, and Peipei Ping.
    Kaiser P; Mayor T
    Mol Cell Proteomics; 2011 May; 10(5):R110.003863. PubMed ID: 20834021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the ubiquitin proteasome system in hematologic malignancies.
    Sahasrabuddhe AA; Elenitoba-Johnson KS
    Immunol Rev; 2015 Jan; 263(1):224-39. PubMed ID: 25510280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. It's all about talking: two-way communication between proteasomal and lysosomal degradation pathways via ubiquitin.
    Liebl MP; Hoppe T
    Am J Physiol Cell Physiol; 2016 Aug; 311(2):C166-78. PubMed ID: 27225656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding cullin-RING E3 biology through proteomics-based substrate identification.
    Harper JW; Tan MK
    Mol Cell Proteomics; 2012 Dec; 11(12):1541-50. PubMed ID: 22962057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Covalent fragment-based ligand screening approaches for identification of novel ubiquitin proteasome system modulators.
    Rothweiler EM; Brennan PE; Huber KVM
    Biol Chem; 2022 Mar; 403(4):391-402. PubMed ID: 35191283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of aberrant proteolysis in lymphomagenesis.
    Sahasrabuddhe AA; Elenitoba-Johnson KS
    Curr Opin Hematol; 2015 Jul; 22(4):369-78. PubMed ID: 26049759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome substrate receptors and their therapeutic potential.
    Osei-Amponsa V; Walters KJ
    Trends Biochem Sci; 2022 Nov; 47(11):950-964. PubMed ID: 35817651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying E3 Ligase Substrates With Quantitative Degradation Proteomics.
    Jordan VN; Ordureau A; An H
    Chembiochem; 2023 Aug; 24(16):e202300108. PubMed ID: 37166757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cullin 5-RING E3 ubiquitin ligases, new therapeutic targets?
    Lamsoul I; Uttenweiler-Joseph S; Moog-Lutz C; Lutz PG
    Biochimie; 2016 Mar; 122():339-47. PubMed ID: 26253693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substrates of the ASB2α E3 ubiquitin ligase in dendritic cells.
    Spinner CA; Uttenweiler-Joseph S; Metais A; Stella A; Burlet-Schiltz O; Moog-Lutz C; Lamsoul I; Lutz PG
    Sci Rep; 2015 Nov; 5():16269. PubMed ID: 26537633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of proteome arrays to globally identify substrates for E3 ubiquitin ligases.
    Persaud A; Rotin D
    Methods Mol Biol; 2011; 759():215-24. PubMed ID: 21863490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recruiting substrates to cullin 4-dependent ubiquitin ligases by DDB1.
    McCall CM; Hu J; Xiong Y
    Cell Cycle; 2005 Jan; 4(1):27-9. PubMed ID: 15655366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzyme-substrate relationships in the ubiquitin system: approaches for identifying substrates of ubiquitin ligases.
    O'Connor HF; Huibregtse JM
    Cell Mol Life Sci; 2017 Sep; 74(18):3363-3375. PubMed ID: 28455558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.